An MRI-based AI tool shows high accuracy in differentiating Parkinsonian syndromes in a large prospective study. Learn more.

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ ...

Hyperbaric Oxygen Therapy (HBOT) is emerging as a science-backed tool to boost brain performance, reverse decline, and ...

Dementia is a highly prevalent condition, affecting 57 million people worldwide, with nearly 10 million new cases each year, ...

Annexon Inc. research and ratings by Barron's. View ANNX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

For years, TRISH has supported research projects and studies that aim to solve the challenges of human exploration in space. To understand how to solve those challenges, we first must know the risks ...